ankylosing spondylitis
Conditions
Interventions
control group:Chinese medicine placebo + western medicine standard treatment
test team:Oral Qingreshuji Prescription + Western Medicine Standard Treatment
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ?18–75 years old ; ?Patients met the diagnostic criteria of Western medicine and disease activity, and the VAS score of spinal pain (the second item of BASDAI) was = 40 mm. ?Patients who met the diagnostic criteria of kidney deficiency and dampness-heat syndrome in TCM ; ?voluntary signing of informed consent ; ?Drug cleaning : SASP, methotrexate (MTX), leflunomide (LEF) and other antirheumatic drugs, hormones, biological agents or small molecule targeted drugs were not used more than 1 month before randomization.
Exclusion criteria
Exclusion criteria: ?pregnant or lactating women and mental patients with severe malnutrition or severe damage to the heart, brain, kidney and hematopoietic system ; ?patients with other rheumatic diseases ; ?Patients with severe spinal and hip joint dysfunction who needed surgery during this study ; ?Concurrent NSAIDs use contraindications ; ?contraindications for combined use of biological agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of ASAS20 at week 16; | — |
Countries
China
Contacts
Public ContactKong Weiping
Outcome results
None listed